Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (311-320 of 438) with videos related to

Pageof 44
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2015
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung CancerJean-Louis Pujol, Johan F Vansteenkiste, Tommaso Martino De Pas, et al.
Journal for Immunotherapy of Cancer|October 30, 2023
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trialCaicun Zhou, Minu K Srivastava, Hao Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2016
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of TreatmentCorey J Langer, Coleman Obasaju, Paul Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancerGiorgio Scagliotti, Silvia Novello, Joachim von Pawel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2017
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung CancerMartin Reck, Normand Blais, Erzsebet Juhasz, et al.
The Annals of Thoracic Surgery|November 7, 2025
Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671Moishe Liberman, David R Jones, Heather Wakelee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V Liu, Martin Reck, Aaron S Mansfield, et al.
JAMA Oncology|June 4, 2021
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized TrialSalma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.
Translational Lung Cancer Research|September 21, 2020
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectivesSabine Wessels, Thomas Muley, Petros Christopoulos, et al.
The Lancet. Respiratory Medicine|March 30, 2019
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony S K Mok, Makoto Nishio, et al.
Pageof 44

Showing results (311-320 of 438) with videos related to

Sort By:
Pageof 44
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2015
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung CancerJean-Louis Pujol, Johan F Vansteenkiste, Tommaso Martino De Pas, et al.
Journal for Immunotherapy of Cancer|October 30, 2023
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trialCaicun Zhou, Minu K Srivastava, Hao Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2016
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of TreatmentCorey J Langer, Coleman Obasaju, Paul Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancerGiorgio Scagliotti, Silvia Novello, Joachim von Pawel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2017
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung CancerMartin Reck, Normand Blais, Erzsebet Juhasz, et al.
The Annals of Thoracic Surgery|November 7, 2025
Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671Moishe Liberman, David R Jones, Heather Wakelee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V Liu, Martin Reck, Aaron S Mansfield, et al.
JAMA Oncology|June 4, 2021
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized TrialSalma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.
Translational Lung Cancer Research|September 21, 2020
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectivesSabine Wessels, Thomas Muley, Petros Christopoulos, et al.
The Lancet. Respiratory Medicine|March 30, 2019
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony S K Mok, Makoto Nishio, et al.
Pageof 44